KN 069
Alternative Names: KN-069Latest Information Update: 14 Aug 2024
Price :
$50 *
At a glance
- Originator Alphamab Oncology
- Class Monoclonal antibodies; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 14 Aug 2024 Phase-I clinical trials in Obesity (In volunteers) in China (SC) (CTR20242623) (NCT06547775)